Divine CBD Feminized

Divine CBD is a CBD-dominant 43/57 cultivar with 13.2% CBD and 1.2% THC. That ratio matters: with THC well under 1%, Divine CBD produces calm, focused, daytime-appropriate effects without the high you would get from a recreational strain. Customers who want the balancing qualities of high-CBD genetics, focus and body relaxation without psychoactivity, choose CBD-rich strains like this one.

• Total CBD: 13.2%
• Total THC: 1.2%
• Dominant terpenes: Myrcene, Bisabolol, Linalool

Divine CBD feminized seeds flower in 6-8 weeks. Published indoor yield: 600 g/m2. Published outdoor yield: Up to 500 gr. Published height: Short. Those are figures published by the seed bank cited on this page, not measurements of our own stock. Rated intermediate difficulty. Feminized genetics are produced to favor female plants, and the photoperiod growth pattern responds well to LST, topping, and SCROG training.

CBD-rich strains share the same cultivation needs as recreational cannabis, consistent feeding (EC 1.0–1.4 in veg, 1.4–1.8 in flower), 6.0–6.5 pH, and standard light cycles (18/6 veg, 12/12 flower). Final cannabinoid expression is most consistent when night temperatures drop 8–10°F below day temperatures in the last two weeks before harvest.

With only 1.2% THC, Divine CBD delivers focused, calm sensations without the cerebral high of recreational cannabis. The 13.2% CBD content is what produces the felt effect: a smooth body-relaxation curve, mental clarity, and a gentle elevation of mood. This is the chemistry profile most associated with:

• Daytime use, focus and clarity without psychoactivity
• A calm, clear-headed, low-intensity character
• A smooth, non-intoxicating body-relaxation curve
• A heavier, more relaxing body effect at higher doses (without next-day grogginess)

Dominant terpenes: Myrcene (primary), Bisabolol (secondary), Linalool (tertiary). High-CBD strains lean toward calming, grounding terpene profiles, Myrcene contributes a soft, resinous note while Bisabolol and Linalool add layered complexity that develops fully during a 3–4 week jar cure.